PAR-25-074-Full-Announcement.html

This document is a Notice of Funding Opportunity (NOFO) for the federal grant program "Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)". The NOFO is solicitation number PAR-25-074, assigned to federal grant program 93.394 "Cancer Detection and Diagnosis Research" under the Department of Health and Human Services National Institutes of Health.

The NOFO invites applications to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. The UH2 phase supports analytical validation of assays within 2 years, while the UH3 phase supports clinical validation of analytically validated assays for up to 3 years using biospecimens from clinical trials or studies. Eligible applicant types include county governments, higher education institutions, 501(c)(3) nonprofits, and other organizations. Projects proposed must involve multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists.